NCT01531530View on ClinicalTrials.gov

Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Shigella
Interventions
BIOLOGICAL

CVD 1208S, a Shigella flexneri 2a live, oral vaccine

The vaccine is mixed with salt water and given by mouth.

OTHER

Placebo

Corn starch and baking soda are mixed with salt water and given by mouth.

Trial Locations (2)

21201

Shin Nippon Biomedical Laboratories, LTD. (SNBL) Inpatient Facility, Baltimore

University of Maryland, Baltimore Center for Vaccine Development, Baltimore

All Listed Sponsors
collaborator

PATH

OTHER

lead

University of Maryland, Baltimore

OTHER

NCT01531530 - Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP | Biotech Hunter | Biotech Hunter